Evidence map›Paper›PMID 40284414›Full record

ArticlePharmaceutics2025

Pharmacokinetics, Pharmacodynamics, and Bioequivalence of Test Insulin Glargine Versus Reference Preparation (Lantus

Zhongping Li, Min Liu, Yi Tao, Lei Wan, Yuan Chen, Mingxue Zhu, Hongtao Zhao, Chengyong Tang

Abstract read
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhongping LiPhase I Clinical Trial Center, Bishan Hospital of Chongqing Medical University, Chongqing 402760, China.
Min LiuPhase I Clinical Trial Center, Bishan Hospital of Chongqing Medical University, Chongqing 402760, China.
Yi TaoOffice of Academic Research, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Lei WanPhase I Clinical Trial Center, Bishan Hospital of Chongqing Medical University, Chongqing 402760, China.
Yuan ChenPhase I Clinical Trial Center, Bishan Hospital of Chongqing Medical University, Chongqing 402760, China.
Mingxue ZhuPhase I Clinical Trial Center, Bishan Hospital of Chongqing Medical University, Chongqing 402760, China.ORCID 0000-0003-1579-5419
Hongtao ZhaoPhase I Clinical Trial Center, Bishan Hospital of Chongqing Medical University, Chongqing 402760, China.
Chengyong TangPhase I Clinical Trial Center, Bishan Hospital of Chongqing Medical University, Chongqing 402760, China.

Funding

Municipal Postgraduate Joint Training Base of Chongqing Medical University No. lpjd202306the Natural Science Foundation of Chongqing No. CSTB2023NSCQ-LZX0019the Scientific Research and Innovation Team Program of Bishan Hospital of Chongqing Medical University No. BYKY-CX2023003the Senior Medical Talents Program of Chongqing for Young and Middle-aged No. 2020GDRC017the Special Research Program for Graduate Student Supervisors of Bishan Hospital of Chongqing Medical University No. BYKY-DS2023010
6 · The paper itself

Abstract

The aim of this study was to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of two insulin glargine preparations in healthy Chinese male subjects.

Indexed as

diabeteseuglycemic clampinsulin glarginepharmacodynamicspharmacokinetics

Identifiers

PMID40284414
PMCPMC12030383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.